Lurasidone Augmentation of Clozapine in Refractory Schizophrenia
Authors:
- 1 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (2) , 157-160
Abstract
Purpose: Clozapine represents the criterion standard therapy for patients with treatment-resistant schizophrenia. Unfortunately, a significant percentage of such patients are also partial responders to clozapine. Consequently, several augmentation strategies have been proposed with various and sometimes controversial efficacy. Among these add-on treatments, lurasidone has been recently introduced and could represent a potential option, especially for the additional positive effect on cognitive symptoms. Methods: This case series aims to determine possible advantages of lurasidone augmentation in four patients treated with clozapine, who were diagnosed with treatment-resistant schizophrenia. Positive and Negative Syndrome Scales were used to evaluate psychopathology, the Udvalg for Kliniske Undersøgelser scale for tolerability and safety. Finding: All patients achieved a significant reduction of both positive and negative symptoms, with no significant adverse effects to be reported. Implications: Our observation suggests that lurasidone can lead to clinically significant improvements in psychopathology with a good tolerability profile when added to clozapine.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in SchizophreniaJAMA Psychiatry, 2017
- Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-AnalysisThe Canadian Journal of Psychiatry, 2017
- Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychosesPsychological Medicine, 2016
- Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5‐HT)2A and DA D2 antagonism and 5‐HT1A partial agonismJournal of Neurochemistry, 2013
- Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled studyPsychopharmacology, 2012
- Long-term safety and tolerability of lurasidone in schizophreniaInternational Clinical Psychopharmacology, 2012
- Treatment-Resistant SchizophreniaPsychiatric Clinics of North America, 2007
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designControlled Clinical Trials, 2004
- Treatment-Resistant Schizophrenia - The Role of ClozapineCurrent Medical Research and Opinion, 1997
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987